Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Regression of tumoral calcinosis after the appropriate control of a deranged mineral and bone metabolism, in conjugation with cinacalcet hydrochloride treatment, in a chronic hemodialysis patient.

Yamada S, Tsuruya K, Kitazono T.

Ther Apher Dial. 2013 Jun;17(3):348-9. doi: 10.1111/1744-9987.12035. Epub 2013 Mar 28. No abstract available.

PMID:
23735152
2.

Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism.

Tsuruta Y, Okano K, Kikuchi K, Tsuruta Y, Akiba T, Nitta K.

Clin Exp Nephrol. 2013 Feb;17(1):120-6. doi: 10.1007/s10157-012-0665-8. Epub 2012 Jul 26.

PMID:
22833360
3.

Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study.

Fukagawa M, Fukuma S, Onishi Y, Yamaguchi T, Hasegawa T, Akizawa T, Kurokawa K, Fukuhara S.

Clin J Am Soc Nephrol. 2012 Sep;7(9):1473-80. Epub 2012 Jul 19.

4.

Decrease of serum sphingosine-1-phosphate levels in hemodialysis patients with secondary hyperparathyroidism treated with cinacalcet.

Yokoyama K, Ohkido I, Iwamoto T, Ishida M, Urashima M, Hosoya T.

Clin Nephrol. 2012 Jul;78(1):85-6. No abstract available.

5.

The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.

Li D, Shao L, Zhou H, Jiang W, Zhang W, Xu Y.

Endocrine. 2013 Feb;43(1):68-77. doi: 10.1007/s12020-012-9711-2. Epub 2012 Jun 6.

PMID:
22669774
6.

Cinacalcet improves control of secondary hyperparathyroidism in peritoneal dialysis: a multicenter study.

Portolés J, López-Sánchez P, Bajo MA, Castellano I, del Peso G, Rodríguez JR, Ribera M, Ortigosa A, Selgas R.

Perit Dial Int. 2012 Mar-Apr;32(2):208-11. doi: 10.3747/pdi.2011.00017. No abstract available.

7.

Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.

Iseki K.

Expert Opin Pharmacother. 2008 Mar;9(4):601-10. doi: 10.1517/14656566.9.4.601. Review.

PMID:
18312161
8.

Cinacalcet for secondary hyperparathyroidism: from improved mineral levels to improved mortality?

Vervloet MG, du Buf-Vereijken PW, Potter van Loon BJ, Manamley N, Reichert LJ, Smak Gregoor PJ.

Neth J Med. 2013 Sep;71(7):348-54. Review.

9.

What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?

Moe SM, Thadhani R.

Curr Opin Nephrol Hypertens. 2013 Nov;22(6):651-5. doi: 10.1097/MNH.0b013e328365b3a3. Review.

10.

[Calcimimetic drugs in stage 3-5 chronic kidney disease].

Grzegorzewska AE, Niepolski L.

Pol Merkur Lekarski. 2012 Apr;32(190):260-2. Review. Polish.

PMID:
22708286
11.

[Treatment with cinacalcet in secondary hyperparathyroidism for dialysis patients: The will is good--but what about the evidence?].

Bárány P, Elinder CG, Samuelsson O.

Lakartidningen. 2013 Aug 21-Sep 3;110(34-35):1481-3. Swedish. No abstract available.

PMID:
24044187
12.

A patient undergoing chronic dialysis whose renal anemia was successfully corrected by treatment with cinacalcet.

Oshiro Y, Tanaka H, Okimoto N.

Clin Exp Nephrol. 2011 Aug;15(4):607-10. doi: 10.1007/s10157-011-0433-1. Epub 2011 Apr 1.

PMID:
21455660
13.

[Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].

Mercadal Orfila G, Blasco Mascaró I.

Farm Hosp. 2012 Jan-Feb;36(1):11-5. doi: 10.1016/j.farma.2010.10.008. Epub 2011 Apr 22. Spanish.

PMID:
21514862
14.

Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism.

Behets GJ, Spasovski G, Sterling LR, Goodman WG, Spiegel DM, De Broe ME, D'Haese PC.

Kidney Int. 2015 Apr;87(4):846-56. doi: 10.1038/ki.2014.349. Epub 2014 Oct 22.

15.

Change in coronary artery calcification score due to cinacalcet hydrochloride administration.

Tsuruta Y, Ohbayashi T, Fujii M, Myochin H, Mizutani R, Narita M, Maeda K.

Ther Apher Dial. 2008 Oct;12 Suppl 1:S34-7. doi: 10.1111/j.1744-9987.2008.00629.x.

PMID:
19032525
16.
17.

Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.

Wheeler DC, London GM, Parfrey PS, Block GA, Correa-Rotter R, Dehmel B, Drüeke TB, Floege J, Kubo Y, Mahaffey KW, Goodman WG, Moe SM, Trotman ML, Abdalla S, Chertow GM, Herzog CA; EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial Investigators.

J Am Heart Assoc. 2014 Nov 17;3(6):e001363. doi: 10.1161/JAHA.114.001363. Erratum in: J Am Heart Assoc. 2015 Jan;4(1):e000570.

18.

Regression of vascular calcification in a patient treated with cinacalcet: a case report.

Salgueira M, Martínez AI, Milán JA.

Nefrologia. 2011;31(5):602-6. doi: 10.3265/Nefrologia.pre2011.May.10869. English, Spanish.

19.

Chronic hemodialysis patients without marked elevation of intact parathyroid hormone are also good candidates for early intervention with cinacalcet.

Nishida H, Masakane I, Kudo K, Ito M, Tanida H, Koshika M, Nishida W, Tomita Y.

Ther Apher Dial. 2013 Jun;17(3):325-31. doi: 10.1111/1744-9987.12000. Epub 2013 Jan 22.

PMID:
23735149
20.

Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism.

Komaba H, Koizumi M, Tanaka H, Takahashi H, Sawada K, Kakuta T, Fukagawa M.

Nephrol Dial Transplant. 2012 May;27(5):1967-9. doi: 10.1093/ndt/gfr645. Epub 2011 Dec 1.

Items per page

Supplemental Content

Write to the Help Desk